How big is the antibody drug conjugates contract manufacturing market today, and what are its future growth expectations?
The antibody drug conjugates contract manufacturing market size has grown rapidly in recent years. It will grow from $9.57 billion in 2024 to $10.55 billion in 2025 at a compound annual growth rate (CAGR) of 10.2%. The growth in the historic period can be attributed to increasing prevalence of cancer, growing demand for targeted therapies, improvements in antibody drug conjugates, rising investment in research and development, regulatory approvals of new ADCs, and the expansion of pharmaceutical companies.
The antibody drug conjugates contract manufacturing market size is expected to see strong growth in the next few years. It will grow to $15.37 billion in 2029 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to anticipated growth of personalized medicine, expanding applications beyond oncology, increasing collaborations between biotech and pharma companies, rising adoption of ADCs in clinical trials, growing emphasis on cost-effective manufacturing solutions. Major trends in the forecast period include advancements in biomarker identification, advancements in biotechnology, rising adoption of next-generation ADC technologies, advancements in linker and payload technologies, integration of artificial intelligence for drug development.
Get Your Free Sample of The Global Antibody Drug Conjugates Contract Manufacturing Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18954&type=smp
What have been the primary factors driving the antibody drug conjugates contract manufacturing market’s growth?
The growing biopharmaceutical industry is expected to propel the growth of the antibody-drug conjugates contract manufacturing market going forward. The biopharmaceutical industry is a sector focused on developing, producing, and commercializing drugs derived from biological sources, utilizing biotechnology and molecular biology to create innovative therapies and treatments. The biopharmaceutical industry is increasing due to rapid advancements in biotechnology, growing demand for personalized medicine, and rising investments in research and development for innovative therapies and treatments. Antibody-drug conjugates (ADCs) contract manufacturing supports the biopharmaceutical industry by offering specialized production services that facilitate developing and commercializing these advanced therapies. Biopharmaceutical companies can efficiently scale up production and ensure high-quality standards while concentrating on their core areas of research and development. For instance, in May 2024, according to the Department of Health and Social Care, a UK-based government department, the core biopharmaceutical sector earned £46.7 billion ($59.32 billion) in revenue in 2021/22, accounting for 43% of the whole life sciences industry. Therefore, the growing biopharmaceutical industry drives the growth of the antibody-drug conjugates contract manufacturing market.
What are the key segments within the antibody drug conjugates contract manufacturing market?
The antibody drug conjugates contract manufacturingmarket covered in this report is segmented –
1) By Type: Immunoglobulin G1(Igg1), Immunoglobulin G4(Igg4)
2) By Linker: Cleavable Linker, Non-Cleavable Linker
3) By Condition: Myeloma, Lymphoma, Breast Cancer, Other Conditions
4) By Phase: Clinical, Commercial
Order your report now for swift delivery
Which key players are shaping the antibody drug conjugates contract manufacturing market?
Major companies operating in the antibody drug conjugates contract manufacturing market are AbbVie Inc., Eli Lilly and Company, Gilead Sciences Inc., Merck KGaA, Boehringer Ingelheim, Recipharm AB, Sigma-Aldrich, Sartorius AG, Curia, Lonza Group AG, Catalent Inc., KBI Biopharma, Alcami Corporation, Formosa Laboratories, BioVectra Inc., Axplora, Abzena PLC, ImmunoGen Inc., EirGenix Inc., Avid Bioservices Inc., Mersana Therapeutics, Cerbios-Pharma SA, Creative Biolabs, Aurigene Pharmaceutical Services Ltd., Sterling Pharma Solutions
How will emerging trends drive the antibody drug conjugates contract manufacturing market throughout the forecast period?
Major companies operating in the antibody-drug conjugates contract manufacturing market are focused on developing innovative products, such as single-use reactors, to enhance production flexibility, reduce contamination risks, and streamline the manufacturing process, ultimately improving the efficiency and scalability of ADC production. Single-use reactors are revolutionizing the field of antibody-drug conjugates (ADCs) contract manufacturing by providing a flexible, efficient, and contamination-free solution for producing these complex biologics. For instance, in September 2024, MilliporeSigma, a US-based life science company, launched the Mobius ADC Reactor, a single-use reactor. Mobius ADC Reactor is specifically designed to manufacture antibody-drug conjugates (ADCs) efficiently. The Mobius ADC Reactor integrates advanced mixing and control technologies that streamline conjugation, enhance scalability, and improve consistency. This innovative reactor supports higher yields and better quality control in ADC production, addressing the growing demand for targeted cancer therapies with improved safety and efficacy.
How do regional factors impact the antibody drug conjugates contract manufacturing market, and which region is the largest contributor?
North America was the largest region in the antibody drug conjugates contract manufacturing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antibody drug conjugates contract manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Antibody Drug Conjugates Contract Manufacturing Market Report 2025 Offer?
The antibody drug conjugates contract manufacturing market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Antibody-drug conjugates (ADC) contract manufacturing refers to the outsourced production services provided by specialized contract development and manufacturing organizations (CDMOs) to create antibody-drug conjugates. ADCs are complex biopharmaceuticals that combine an antibody with a cytotoxic drug, designed to target and destroy specific cancer cells while minimizing damage to healthy cells.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18954
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
